Fosphenytoin vs Oxcarbazepine (Oxtellar XR)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Voltage-gated sodium channel · full Epilepsy pipeline

Fosphenytoin

Marketed by Pfizer

Approved in Epilepsysmall molecule
Partial signal

NCT01960075 · Phase 3 · completed

This randomized, triple-blind phase 3 trial (ESETT) compared intravenous fosphenytoin, valproic acid and levetiracetam in 478 enrolments with benzodiazepine-refractory status epilepticus. The primary endpoint was clinical cessation of status epilepticus within 60 minutes. The trial stopped early for futility under a prespecified rule; in the intention-to-treat analysis of the first 400 patients, seizures stopped in 53 of 118 participants on fosphenytoin, 56 of 121 on valproic acid and 68 of 145 on levetiracetam, and no arm was shown to be superior.

No aligned efficacy figure on record for this race.

Oxcarbazepine (Oxtellar XR)

Marketed by Supernus Pharmaceuticals

Approved in Epilepsysmall molecule
Partial signal

NCT00772603 · Phase 3 · completed

The trial was randomized, quadruple-blind, placebo-controlled, and included 366 participants, with seizure frequency as a clinical primary endpoint. The 2,400-mg comparison significantly favored oxcarbazepine, while the 1,200-mg comparison did not, so the primary result was mixed rather than consistently positive.

Reported efficacy

Percent Change in Seizure Rate (one year): Percent Change in Seizure Rate (one year): Oxcarbazepine XR -26.3 percentage of change in seizure rate (range -100 to 344.7) (not_applicable)

Result source: NCT00908349

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFosphenytoinOxcarbazepine (Oxtellar XR)
Seizure frequency, % change—Not posted · NCT00908453—Not reported
50% responder rate—Not posted · NCT0090845350% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603
Seizure freedom—Not posted · NCT00908453—Not reported

Seizure frequency, % change

Fosphenytoin
—Not posted · NCT00908453
Oxcarbazepine (Oxtellar XR)
—Not reported

50% responder rate

Fosphenytoin
—Not posted · NCT00908453
Oxcarbazepine (Oxtellar XR)
50% vs 34%+16 vs placebo2400 mg/day · wk 16 · n 109NCT00772603
1 other result
  • 44% vs 34% 1200 mg/day · wk 16 · n 111 · Phase 3 · secondary NCT00772603

Seizure freedom

Fosphenytoin
—Not posted · NCT00908453
Oxcarbazepine (Oxtellar XR)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Fosphenytoin: 3 of 4 rows · Oxcarbazepine (Oxtellar XR): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricFosphenytoinOxcarbazepine (Oxtellar XR)
Dropout rate
38.2%a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
42.3%2400 mg/dayb
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
32.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
16.4%
NCT00908349 · Phase 3 · monotherapy
Discontinued due to AEs
—a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
—400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
30.1%2400 mg/dayb
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
14.8%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
4.7%
NCT00908349 · Phase 3 · monotherapy
Serious AEs
0%a
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
22.2%400mg
NCT01458522 · Phase 2 · registry result, not featured evidence
8.1%2400 mg/dayb
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
5.7%1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
8.4%
NCT00908349 · Phase 3 · monotherapy
Most frequent reported AEs
a
dizziness 9.2%
fatigue 9.2%
burning at the iv site 6.6%
NCT00510783 · Phase 4 · registry result, not featured evidence
show 1 more result
400mg
respiratory failure 6.7%
acute respiratory failure 4.4%
bradycardia 4.4%
NCT01458522 · Phase 2 · registry result, not featured evidence
2400 mg/dayb
dizziness 40.7% (placebo 14.9%)
headache 15.4% (placebo 7.4%)
vomiting 15.4% (placebo 9.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 2 more results
1200 mg/day
dizziness 19.7% (placebo 14.9%)
somnolence 11.5% (placebo 9.1%)
diplopia 9.8% (placebo 4.1%)
NCT00772603 · Phase 3 · Epilepsy · phase 3
dizziness 15.4%
headache 11.2%
diplopia 9.3%
NCT00908349 · Phase 3 · monotherapy

Notes

  1. aPopulation comparability has not been reviewed for these studies.
  2. bPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Fosphenytoin

Seizure Recurrence 24 h 3.9% (n=76) vs 2.4% (n=82) Phenytoin/Fosphenytoin @ 0.142857wk
event count · % of participants
NCT00510783 · Phase 4 · registry result, not featured evidence · converted to % from 3 participants as posted
Seizure-free 54.3% (n=35) vs 62.9% (n=35) fPHT @ 0.14wk400mg
event count · % of participants
NCT01458522 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted
Seizure Burden -0.58 vs -0.54 fPHT per hour @ 0.14wk400mg
absolute change · per hour
NCT01458522 · Phase 2 · registry result, not featured evidence

Oxcarbazepine (Oxtellar XR)

Seizure 50 50% (n=109) vs 34% (n=117) placebo @ 16wk2400 mg/day
responder rate · % of participants
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
44% (n=111) vs 34% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 14% (n=111) vs 4% (n=117) placebo @ 16wk2400 mg/day
absolute value · percentage points
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
6% (n=109) vs 4% (n=117) placebo @ 16wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3
Seizure Free 17% (n=88) vs 7% (n=109) placebo @ 12wk2400 mg/day
absolute value · percentage points
Maintenance
NCT00772603 · Phase 3 · Epilepsy · phase 3
show 1 more result
4% (n=97) vs 7% (n=109) placebo @ 12wk1200 mg/day
NCT00772603 · Phase 3 · Epilepsy · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fosphenytoin's landscape · Oxcarbazepine (Oxtellar XR)'s landscape